KIF9‑AS1 promotes nasopharyngeal carcinoma progression by suppressing miR‑16
- Huizeng You
- Shuyong Wang
- Sa Yu
Affiliations: Department of Otolaryngology, Weifang Traditional Chinese Hospital, Weifang, Shandong 261041, P.R. China, Department of Otorhinolaryngology‑Head and Neck Surgery, Zhuji People's Hospital of Zhejiang Province, Zhuji, Zhejiang 311800, P.R. China
- Published online on: September 15, 2020 https://doi.org/10.3892/ol.2020.12104
Copyright: © You
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Long non‑coding RNAs (lncRNAs) have been reported to serve a crucial role in the progression of nasopharyngeal carcinoma (NPC); however, the underlying molecular mechanisms of lncRNA KIF9‑AS1 in the tumorigenesis of NPC remains poorly understood. Reverse transcription‑quantitative PCR was used to analyze the expression levels of KIF9‑AS1 and microRNA (miR)‑16, and Cell Counting Kit‑8, wound healing and Transwell assays were used to determine the cell viability, invasion and migration, respectively, of NPC cells. In addition, a dual‑luciferase reporter assay was used to analyze the direct interaction between KIF9‑AS1 and miR‑16. NPC stage was classified according to the seventh edition of the AJCC staging system. The results revealed that KIF9‑AS1 expression levels were upregulated in NPC tissues and cell lines. In addition, miR‑16 was demonstrated to directly interact with KIF9‑AS1 and inhibit KIF9‑AS1 expression levels, whereas the miR‑16 inhibitor rescued the effects of the KIF9‑AS1‑knockdown in NPC cells. Furthermore, the expression levels of KIF9‑AS1 were upregulated, while those of miR‑16 were downregulated in NPC tissues. Notably, the expression levels of KIF9‑AS1 were observed to be significantly more upregulated in advanced tumors (III‑IV vs. I‑II) and patients with high KIF9‑AS1 expression levels exhibited a worse prognosis. In conclusion, the findings of the present study suggested that KIF9‑AS1 may promote the progression of NPC by targeting miR‑16, thus KIF9‑AS1 may be a novel molecular target for NPC therapy.